De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Medpace Holdings Beheer
Beheer criteriumcontroles 4/4
De CEO Medpace Holdings' is August Troendle, benoemd in Jul1992, heeft een ambtstermijn van 32.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.65M, bestaande uit 49.5% salaris en 50.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 17.42% van de aandelen van het bedrijf, ter waarde $ 1.80B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.7 jaar en 6.2 jaar.
Belangrijke informatie
August Troendle
Algemeen directeur
US$1.6m
Totale compensatie
| Percentage CEO-salaris | 49.5% |
| Dienstverband CEO | 32.3yrs |
| Eigendom CEO | 17.4% |
| Management gemiddelde ambtstermijn | 5.7yrs |
| Gemiddelde ambtstermijn bestuur | 6.2yrs |
Recente managementupdates
Recent updates
Medpace Holdings, Inc.'s (NASDAQ:MEDP) Earnings Haven't Escaped The Attention Of Investors
Sep 19
Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Sep 02Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Aug 20Why Medpace Holdings' (NASDAQ:MEDP) Earnings Are Better Than They Seem
Jul 31Medpace Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Jul 25What You Can Learn From Medpace Holdings, Inc.'s (NASDAQ:MEDP) P/E
Jun 18Medpace: Clear Winner If China Blockade Succeeds
Jun 04A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
May 22Does Medpace Holdings (NASDAQ:MEDP) Deserve A Spot On Your Watchlist?
Apr 12Medpace: Exceptional Performance, Almost Fully Priced In
Mar 11Medpace Holdings, Inc.'s (NASDAQ:MEDP) 32% Jump Shows Its Popularity With Investors
Feb 18Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Feb 09A Look At The Intrinsic Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jan 25Should You Be Adding Medpace Holdings (NASDAQ:MEDP) To Your Watchlist Today?
Jan 10Shareholders Should Be Pleased With Medpace Holdings, Inc.'s (NASDAQ:MEDP) Price
Dec 26Should You Investigate Medpace Holdings, Inc. (NASDAQ:MEDP) At US$275?
Nov 08Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 29% Below Their Intrinsic Value Estimate
Oct 23If EPS Growth Is Important To You, Medpace Holdings (NASDAQ:MEDP) Presents An Opportunity
Oct 10Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Aug 27Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Jul 31A Look At The Fair Value Of Medpace Holdings, Inc. (NASDAQ:MEDP)
Jul 18Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Jul 04Is Medpace Holdings (NASDAQ:MEDP) A Risky Investment?
May 25Is Now The Time To Look At Buying Medpace Holdings, Inc. (NASDAQ:MEDP)?
Apr 27An Intrinsic Calculation For Medpace Holdings, Inc. (NASDAQ:MEDP) Suggests It's 28% Undervalued
Apr 12We Ran A Stock Scan For Earnings Growth And Medpace Holdings (NASDAQ:MEDP) Passed With Ease
Mar 27Does Medpace Holdings (NASDAQ:MEDP) Have A Healthy Balance Sheet?
Feb 14What Is Medpace Holdings, Inc.'s (NASDAQ:MEDP) Share Price Doing?
Jan 16Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Could Be 41% Below Their Intrinsic Value Estimate
Jan 03Here's Why We Think Medpace Holdings (NASDAQ:MEDP) Might Deserve Your Attention Today
Dec 20Medpace Holdings (NASDAQ:MEDP) Has A Rock Solid Balance Sheet
Nov 16Growth Investors: Industry Analysts Just Upgraded Their Medpace Holdings, Inc. (NASDAQ:MEDP) Revenue Forecasts By 13%
Nov 03Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$340m |
| Mar 31 2024 | n/a | n/a | US$312m |
| Dec 31 2023 | US$2m | US$814k | US$283m |
| Sep 30 2023 | n/a | n/a | US$273m |
| Jun 30 2023 | n/a | n/a | US$268m |
| Mar 31 2023 | n/a | n/a | US$257m |
| Dec 31 2022 | US$2m | US$770k | US$245m |
| Sep 30 2022 | n/a | n/a | US$227m |
| Jun 30 2022 | n/a | n/a | US$209m |
| Mar 31 2022 | n/a | n/a | US$199m |
| Dec 31 2021 | US$6m | US$697k | US$181m |
| Sep 30 2021 | n/a | n/a | US$182m |
| Jun 30 2021 | n/a | n/a | US$175m |
| Mar 31 2021 | n/a | n/a | US$159m |
| Dec 31 2020 | US$4m | US$608k | US$145m |
| Sep 30 2020 | n/a | n/a | US$124m |
| Jun 30 2020 | n/a | n/a | US$107m |
| Mar 31 2020 | n/a | n/a | US$110m |
| Dec 31 2019 | US$8m | US$504k | US$100m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | n/a | n/a | US$88m |
| Mar 31 2019 | n/a | n/a | US$78m |
| Dec 31 2018 | US$528k | US$420k | US$73m |
| Sep 30 2018 | n/a | n/a | US$61m |
| Jun 30 2018 | n/a | n/a | US$52m |
| Mar 31 2018 | n/a | n/a | US$45m |
| Dec 31 2017 | US$598k | US$419k | US$39m |
Compensatie versus markt: De totale vergoeding ($USD 1.65M ) August } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 13.04M ).
Compensatie versus inkomsten: De vergoeding van August is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
August Troendle (68 yo)
32.3yrs
Tenure
US$1,646,031
Compensatie
Dr. August James Troendle, M.D. serves as Chairman of CinRx Pharma, LLC. He has been the Chairman, Chief Executive Officer at Medpace Holdings, Inc. since July 1992 and served as its President since July 1...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 32.3yrs | US$1.65m | 17.42% $ 1.8b | |
| President | 3.2yrs | US$945.08k | 0.070% $ 7.2m | |
| CFO & Treasurer | 5.7yrs | US$690.48k | 0.019% $ 2.0m | |
| Executive Vice President of Operations | 7.8yrs | US$1.12m | 0.19% $ 19.4m | |
| Chief Compliance Officer | 12.3yrs | US$914.64k | 0.043% $ 4.5m | |
| Chief Information Officer | 3.8yrs | geen gegevens | geen gegevens | |
| Associate Director of Investors Relations | no data | geen gegevens | geen gegevens | |
| Vice President of Business Development & Marketing | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Commercial Operations & Clinical Pharmacology Unit | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer of Medical Department | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Monitoring | no data | geen gegevens | geen gegevens |
5.7yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MEDP is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 32.3yrs | US$1.65m | 17.42% $ 1.8b | |
| Lead Independent Director | 6.2yrs | US$264.98k | 0.0065% $ 674.2k | |
| Independent Director | 6.2yrs | US$217.48k | 0.017% $ 1.7m | |
| Independent Director | 8.3yrs | US$227.35k | 0.0017% $ 175.1k | |
| Independent Director | 8.3yrs | US$234.97k | 0.070% $ 7.3m | |
| Independent Director | 1.8yrs | US$258.37k | 0% $ 0 | |
| Director | less than a year | geen gegevens | geen gegevens |
6.2yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MEDP wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.2 jaar).